title: Paronychia induced by the epidermal growth factor receptor inhibitor cetuximab.
abstract: While the development of epidermal growth factor receptor inhibitors has been hailed as a remarkable triumph in the field of oncology, it has inherited with it a host of cutaneous side-effects that have been increasingly observed in a substantial number of patients in the recent years. One cutaneous manifestation that may inflict significant pain and affect activities of daily living among some of the patients receiving epidermal growth factor receptor inhibitors is paronychia. A case of paronychia associated with the use of cetuximab in the management of KRAS wild-type midrectal adenocarcinoma along with its management has been described.
authors.affiliation: Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Malaysia. lee.gsl@gmail.com
authors.forename: Soo Lin
authors.initials: SL
authors.lastname: Lee
authors.forename: Boon Seang
authors.initials: BS
authors.lastname: Tan
authors.forename: Lee Chin
authors.initials: LC
authors.lastname: Chan
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000201:enzymology; D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000068818:Cetuximab; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D005260:Female; D006801:Humans; D010304:Paronychia / Q000139:chemically induced* / Q000201:enzymology; D012004:Rectal Neoplasms / Q000188:drug therapy / Q000201:enzymology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D066246:ErbB Receptors; D000068818:Cetuximab